Sign In
Buy NAGE
Niagen Bioscience Earnings Calls
| Release date | May 06, 2026 |
| EPS estimate | $0.0600 |
| EPS actual | $0.0700 |
| EPS Surprise | 16.67% |
| Revenue estimate | 31.03M |
| Revenue actual | 31.474M |
| Revenue Surprise | 1.43% |
| Release date | Mar 04, 2026 |
| EPS estimate | $0.0200 |
| EPS actual | $0.0300 |
| EPS Surprise | 50.00% |
| Revenue estimate | 31.701M |
| Revenue actual | 33.839M |
| Revenue Surprise | 6.74% |
| Release date | Nov 04, 2025 |
| EPS estimate | $0.0150 |
| EPS actual | $0.0500 |
| EPS Surprise | 233.33% |
| Revenue estimate | 31.102M |
| Revenue actual | 33.986M |
| Revenue Surprise | 9.27% |
| Release date | Aug 06, 2025 |
| EPS estimate | $0.0200 |
| EPS actual | $0.0400 |
| EPS Surprise | 100.00% |
| Revenue estimate | 30.762M |
| Revenue actual | 31.117M |
| Revenue Surprise | 1.15% |
Last 4 Quarters for Niagen Bioscience
Below you can see how NAGE performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 06, 2025 |
| Price on release | $9.40 |
| EPS estimate | $0.0200 |
| EPS actual | $0.0400 |
| EPS surprise | 100.00% |
| Date | Price |
|---|---|
| Jul 31, 2025 | $9.35 |
| Aug 01, 2025 | $9.04 |
| Aug 04, 2025 | $9.64 |
| Aug 05, 2025 | $9.16 |
| Aug 06, 2025 | $9.40 |
| Aug 07, 2025 | $9.61 |
| Aug 08, 2025 | $9.73 |
| Aug 11, 2025 | $9.82 |
| Aug 12, 2025 | $10.26 |
| 4 days before | 0.535% |
| 4 days after | 9.15% |
| On release day | 2.23% |
| Change in period | 9.73% |
| Release date | Nov 04, 2025 |
| Price on release | $6.95 |
| EPS estimate | $0.0150 |
| EPS actual | $0.0500 |
| EPS surprise | 233.33% |
| Date | Price |
|---|---|
| Oct 29, 2025 | $7.27 |
| Oct 30, 2025 | $7.11 |
| Oct 31, 2025 | $7.54 |
| Nov 03, 2025 | $7.23 |
| Nov 04, 2025 | $6.95 |
| Nov 05, 2025 | $6.88 |
| Nov 06, 2025 | $6.60 |
| Nov 07, 2025 | $6.84 |
| Nov 10, 2025 | $7.10 |
| 4 days before | -4.40% |
| 4 days after | 2.16% |
| On release day | -1.01% |
| Change in period | -2.34% |
| Release date | Mar 04, 2026 |
| Price on release | $4.94 |
| EPS estimate | $0.0200 |
| EPS actual | $0.0300 |
| EPS surprise | 50.00% |
| Date | Price |
|---|---|
| Feb 26, 2026 | $5.18 |
| Feb 27, 2026 | $5.05 |
| Mar 02, 2026 | $4.99 |
| Mar 03, 2026 | $4.87 |
| Mar 04, 2026 | $4.94 |
| Mar 05, 2026 | $5.10 |
| Mar 06, 2026 | $5.06 |
| Mar 09, 2026 | $5.11 |
| Mar 10, 2026 | $5.22 |
| 4 days before | -4.63% |
| 4 days after | 5.67% |
| On release day | 3.24% |
| Change in period | 0.772% |
| Release date | May 06, 2026 |
| Price on release | $4.97 |
| EPS estimate | $0.0600 |
| EPS actual | $0.0700 |
| EPS surprise | 16.67% |
| Date | Price |
|---|---|
| Apr 30, 2026 | $4.73 |
| May 01, 2026 | $4.85 |
| May 04, 2026 | $4.93 |
| May 05, 2026 | $4.82 |
| May 06, 2026 | $4.97 |
| May 07, 2026 | $4.19 |
| May 08, 2026 | $4.17 |
| May 11, 2026 | $3.98 |
| May 12, 2026 | $3.85 |
| 4 days before | 5.07% |
| 4 days after | -22.54% |
| On release day | -15.69% |
| Change in period | -18.60% |
Niagen Bioscience Earnings Call Transcript Summary of Q1 2026
Niagen Bioscience reported Q1 2026 revenue of $31.5M (5% YoY growth excluding the divested reference standard business), net income of $6.3M, $66.5M cash and no debt. Core e-commerce grew 14% YoY with direct-to-consumer outpacing Amazon. Management highlighted strong media coverage and scientific leadership (including a USP monograph for Niagen), and launched new offerings: Niagen+ at-home injection (telehealth and at-home kit) and Niagen Nanocloud topical (wide launch planned for October) — both showing encouraging early demand. The company continues IND-enabling preclinical work aimed at pharmaceutical applications (e.g., ataxia telangiectasia). Management noted competitive pressure from an increase in low-cost NMN products impacting customer acquisition and Amazon ad costs. Gross margin improved slightly to 63.5%. Selling & marketing expense increased as a percent of sales (management plans to invest more in marketing/brand awareness), R&D was up modestly, and G&A rose due to prior-year recovery absence and higher share-based comp. Inventory was higher due to previously committed purchases but is expected to decline through the year. The company reaffirmed full-year revenue growth guidance of 10%–15% and is executing a $20M share repurchase program (Q1 repurchases ~$2.4M).
